Evolving role of immunology in chronic pain medicine: tissue necrosis factor and interleukin modulatory treatments

Abstract

Our immune system acts to protect us in times of stress and traumatic injury. As part of the immune response, the body produces various cytokines, which mediate or modulate immune functions. Such cytokines include tumor necrosis factor (TNF) and interleukin 6 (IL-6) and IL-17. These cytokines can also act on the nervous system to influence pain perception. TNF-α triggers an inflammatory response and two forms of programmed cell death, apoptosis and necroptosis, depending on the pathological state. For individuals with chronic conditions relating to immune deficiency, the actions of these cytokines can present as chronic pain states, significantly altering quality of life. One attractive potential solution for treating this immune linked pain is by altering signaling pathways of pain-enhancing cytokines. Infliximab and etanercept are TNF inhibitors that are currently on the market for use in the treatment of chronic pain. Secukinumab and tocilizumab serve as IL inhibitors, utilized for a similar purpose. These novel immunotherapies have shown efficacy in numerous clinical studies with acceptable side effect profiles. In this review, we summarize the pharmacological profiles of these drugs and discuss their usage in treating chronic pain.

Keywords

Cytokine modulation / chronic pain / TNF inhibitors / interleukin modulation / immunotherapy

References

[1] Pain [Internet]. Bethesda: National Institute of Neurological Disorders and Stroke; [cited 2024 Feb 22]. Available from: https://www.ninds.nih.gov/health-information/disorders/pain

[2] Chronic Pain [Internet]. Cleveland: Cleveland Clinic; c2024 [cited 2024 Feb 21]. https://my.clevelandclinic.org/health/diseases/4798-chronic-pain

[3] Chronic Pain and High-impact Chronic Pain Among U.S. Adults, 2019 [Internet]. CDC; [cited 2024 Feb 21]. https://www.cdc.gov/nchs/products/databriefs/db390.htm

[4] Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021; 397: 2082-97.

[5] Garland EL. Pain processing in the human nervous system: a selective review of nociceptive and biobehavioral pathways. Prim Care. 2012; 39: 561-71.

[6] Brodal P. The Central Nervous System. 5th ed. Oxford University Press; 2010.

[7] Tennant F. The physiologic effects of pain on the endocrine system. Pain Ther. 2013; 2: 75-86.

[8] InformedHealth.org. In brief: The innate and adaptive immune systems. Cologne: Institute for Quality and Efficiency in Health Care (IQWiG); 2006.

[9] An overview of the innate immune system [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.uptodate.com/contents/an-overview-of-the-innate-immune-system

[10] Netea MG, van de Veerdonk FL, van der Meer JW. Primary immunodeficiencies of pattern recognition receptors. J Intern Med. 2012; 272: 517-27.

[11] Silva MT. When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol. 2010; 87: 93-106.

[12] Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol. 2008; 26: 421-52.

[13] Acute phase reactants [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.uptodate.com/contents/acute-phase-reactants

[14] Ruddle NH, Akirav EM. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J Immunol. 2009; 183: 2205-12.

[15] The adaptive cellular immune response: T cells and cytokines [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.uptodate.com/contents/the-adaptive-cellular-immune-response-t-cells-and-cytokines

[16] Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. Tumour necrosis factor signalling in health and disease. F1000Res. 2019; 8: F1000 Faculty Rev-111.

[17] Chu WM. Tumor necrosis factor. Cancer Lett. 2013; 328: 222-5.

[18] Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport. 1996; 7: 2897-901.

[19] Sorkin LS, Doom CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst. 2000; 5: 96-100.

[20] Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology. 2001; 56: 1371-7.

[21] Leung L, Cahill CM. TNF-alpha and neuropathic pain——a review. J Neuroinflammation. 2010; 7: 27.

[22] Shamji MF, Jing L, Chen J, Hwang P, Ghodsizadeh O, Friedman AH, et al. Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier. J Neurosurg Spine. 2008; 9: 221-8.

[23] Sommer C, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001; 913: 86-9.

[24] Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett. 2005; 379: 209-13.

[25] Infliximab (including biosimilars): Drug information [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.medilib.ir/uptodate/show/8984

[26] Etanercept (including biosimilars available in Canada): Drug information [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.medilib.ir/uptodate/show/8925

[27] Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimäki J, Paimela L, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine (Phila Pa 1976). 2004; 29: 2115-9.

[28] Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC 3rd, Griffith S, et al. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology. 2007; 107: 99-105.

[29] Adalimumab (including biosimilars): Drug information [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.medilib.ir/uptodate/show/8583

[30] certolizumab pegol (Rx) [Internet]. WebMD LLC; c2024 [cited 2024 Feb 29]. Available from: https://reference.medscape.com/drug/cimzia-certolizumab-pegol-343185

[31] Golimumab Injection [Internet]. American Society of Health-System Pharmacists, Inc.; [cited 2024 Feb 29]. Available from: https://medlineplus.gov/druginfo/meds/a610010.html

[32] Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, et al. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study. Ther Adv Musculoskelet Dis. 2019; 11: 1759720X19831151.

[33] Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015; 67: 1424-37.

[34] Justiz Vaillant AA, Qurie A. Interleukin. Treasure Island (FL): StatPearls Publishing; 2024.

[35] Sebba A. Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis. Open Access Rheumatol. 2021; 13: 31-43.

[36] Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018; 281: 8-27.

[37] Totsch SK, Sorge RE. Immune System Involvement in Specific Pain Conditions. Mol Pain. 2017; 13: 1744806917724559.

[38] Jiang X, Zhou R, Zhang Y, Zhu T, Li Q, Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol. 2022; 13: 999407.

[39] Kim CF, Moalem-Taylor G. Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. J Pain. 2011; 12: 370-83.

[40] Richter F, Natura G, Ebbinghaus M, von Banchet GS, Hensellek S, König C, et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 2012; 64: 4125-34.

[41] Cui JG, Holmin S, Mathiesen T, Meyerson BA, Linderoth B. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain. 2000; 88: 239-48.

[42] Vazquez E, Kahlenbach J, Segond von Banchet G, König C, Schaible HG, Ebersberger A. Spinal interleukin-6 is an amplifier of arthritic pain in the rat. Arthritis Rheum. 2012; 64: 2233-42.

[43] Havrdová E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016; 263: 1287-95.

[44] Luo H, Liu H, Zhang W, Matsuda M, Lv N, Chen G, et al. Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy. Cell Rep. 2019; 29: 2384-97.e5.

[45] Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016; 138: 984-1010.

[46] Sainoh T, Orita S, Miyagi M, Sakuma Y, Yamauchi K, Suzuki M, et al. Interleukin-6 and interleukin-6 receptor expression, localization, and involvement in pain-sensing neuron activation in a mouse intervertebral disc injury model. J Orthop Res. 2015; 33: 1508-14.

[47] Sarilumab: Drug information [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.medilib.ir/uptodate/show/113355

[48] Tocilizumab (including biosimilars): Drug information [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://www.medilib.ir/uptodate/show/10208

[49] Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J. 2012; 21: 2079-84.

[50] Anakinra: Drug information [Internet]. UpToDate; c2024 [cited 2024 Feb 21]. Available from: https://medilib.ir/uptodate/show/9246

[51] Horst RT, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, et al. Host and Environmental Factors Influencing Individual Human Cytokine Responses. Cell. 2016; 167: 1111-24.e13.

[52] Pruett SB, Zheng Q, Fan R, Matthews K, Schwab C. Ethanol suppresses cytokine responses induced through Toll-like receptors as well as innate resistance to Escherichia coli in a mouse model for binge drinking. Alcohol. 2004; 33: 147-55.

[53] Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G. The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol. 2009; 183: 1320-7.

[54] Søegaard EGI, Kan Z, Aass HCD, Koirala R, Hauff E, Thapa SB. Abnormal Cytokines in Trauma Patients Explained by Obesity, Musculoskeletal Disease, Smoking, and Lung Disease. Neuropsychobiology. 2022; 81: 516-30.

[55] Balevic SJ, Becker ML, Gonzalez D, Funk RS. Low Etanercept Concentrations in Children With Obesity and Juvenile Idiopathic Arthritis. J Pediatr Pharmacol Ther. 2021; 26: 809-14.

[56] Webster LR, Belfer I. Pharmacogenetics and Personalized Medicine in Pain Management. Clin Lab Med. 2016; 36: 493-506.

[57] Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013; 9: e1003394.

[58] Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, Plaza-Plaza JC, Calleja-Hernández MŸ. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res. 2016; 111: 264-71.

[59] Felis-Giemza A, Massalska M, Roszkowski L, Romanowska-Próchnicka K, Ciechomska M. Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases. J Inflamm Res. 2023; 16: 3949-65.

[60] Almeida C, Choy EHS, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016; 2016: CD008334.

[61] Bakrim S, Benkhaira N, Bourais I, Benali T, Lee L, Omari NE, et al. Health Benefits and Pharmacological Properties of Stigmasterol. Antioxidants (Basel). 2022; 11: 1912.

[62] Si W, Chen Z, Bei J, Chang S, Zheng Y, Gao L, et al. Stigmasterol alleviates neuropathic pain by reducing Schwann cell-macrophage cascade in DRG by modulating IL-34/CSF1R. CNS Neurosci Ther. 2024; 30: e14657.